Uncategorized

Medtech – June 23 | Summer showcase 2022

Company介绍Intro
BD (China)BD是一家全球化的医疗技术公司,通过改善医学发现方法、医疗诊断效果和护理质量以引领世界健康。BD在保护患者和医护人员安全、强化医学研究和临床实验室建设领域为行业所瞩目。公司提供创新的解决方案,以帮助推进医学和基因组学研究、加强传染性疾病和癌症的诊断、改善药物管理、促进感染预防、为手术和介入治疗提供工具,并支持糖尿病管理。BD is a global medical technology company that leads the world in health by improving medical discovery methods, medical diagnostic outcomes and quality of care. BD is noted in the industry for protecting the safety of patients and healthcare professionals, enhancing medical research and building clinical laboratories. The company provides innovative solutions to help advance medical and genomic research, enhance the diagnosis of infectious diseases and cancers, improve drug management, promote infection prevention, provide tools for surgical and interventional treatments, and support diabetes management.
Shanghai HeartCare Medical心玮医疗是一家创新的医疗设备公司,致力于改善创新医疗技术的可及性,保护生命和健康。在五年多的时间里,我们已经在中国的神经介入市场建立了先锋领导地位,并成功地提供了国内第一个一站式的中风治疗和预防解决方案。利用我们在研发、生产和商业化方面的优势,我们努力满足中国临床医生和患者未被满足的需求,同时经营各种新兴业务部门,包括神经介入、心脏介入、肺部介入和计算机辅助技术等。Shanghai HeartCare Medica is are an innovative medical device company committed to improving the accessibility of innovative medical technologies and protecting lives and health. Over the period of more than five years, we have established a pioneering leadership position in China’s neuro-interventional market, and successfully provided the first domestic one-stop solution for stroke treatment and prevention. Leveraging our advantage in R&D, manufacturing and commercialization, we strive to fulfill the unmet needs of clinicians and patients in China while operating a variety of emerging business units extending from Neuro-intervention, Cardiac intervention, Pulmonary intervention to Computer-assisted technology, and more
M3dicineM3dicine是世界上仅有的3家具有为全球市场提供设计和制造的基于AI技术的被FDA认可的医疗设备的公司之一。
该公司开发了一种AI辅助人工智能电子听诊器系统,为临床检查、远程健康评估以及患者管理提供了一个强大的系统工具,同时也提高了医务人员的工作效率并改善了工作流程。能够在20秒内通过超级灵敏的过滤器捕获患者心、肺细微声音并放大,然后运用AI数据智能分析,向医务工作者提供针对心血管和呼吸系统的用于辅助诊断的建议。
FluidIQFluidIQ是一家特拉华州的公司,致力于解决优质、可用和临床有用的复苏器的短缺问题。FluidIQ在流体力学技术的重大突破性发现的其产品组合平台的基础,具有超越医疗技术领域的潜在应用。其最初的设备(HOPE inVent)是一个唇膏大小的自动、压力控制、压力循环的呼吸器,没有活动部件,只需要氧气或压缩空气就可以操作。同样,它没有活动部件、电池、电子器件或控制装置。流体学的利用使得它的设计在通气过程中可以保护肺部,而不像目前使用的护理标准(袋阀式面罩或BVM)需要手动通气,并在过去70年的时间里没有发生变化。FluidIQ is a Delaware C-Corporation that was incorporated in 2020, devoted to solve the shortage of quality, available and clinically useful resuscitators. A breakthrough discovery using fluidics technology is the basis for fluidIQ’s intellectual property and planned product portfolio platform. Our initial device (HOPE inVent) is a lipstick-sized automatic, pressure controlled, pressure cycled ventilator with no moving parts and requiring only oxygen or compressed air to operate. Again, it has no moving parts, batteries, electronics or controls. The utilization of fluidics allows its design to be lung protective during ventilation unlike the current standard of care (bag valve masks or BVM) used and virtually unchanged in manual ventilation for the past 70 years.
Shangyi Technology尚医信息科技公司是“数字疗法”术康APP的研发企业,致力于通过智能生活方式的干预,为慢性疾病、慢性疼痛患者以及需要延缓大脑功能衰退的人群提供远程智能康复治疗。公司构建了“智能硬件+手机App+医学运动治疗中心”的运动康复和慢病管理体系,致力于通过智能软硬件的技术支持,结合远程监测与居家康复,通过“有效运动”帮助大众解决在亚健康、三高、运动损伤及预防等领域的健康问题。Shangyi Technology is dedicated to providing remote intelligent rehabilitation treatment for chronic diseases, chronic pain patients and people who need to slow down the decline of brain function through intelligent lifestyle interventions. The company has built a sports rehabilitation and chronic disease management system of “smart hardware + app + medical sports therapy centre”, and is committed to helping the public solve their problems of sub-health, sports injuries and chronic pain through “effective exercise”.
Nanjing ChuangteFounded in February 2019, Chuangte is an innovative biotechnology company specializing in the research and development of new drugs, technology transfer and industrialization of new pharmaceutical products, targeting for oncology, cerebrovascular and respiratory diseases. Their lead asset is the third generation TKI which selectively inhibits EGFR mutations, especially T790M mutation. First line EGFR positive advanced NSCLC; Second line EGFR T790M mutation positive NSCLC. Ph3 is ongoing and NDA is expected in 2023.
Medivir ABMedivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 
OS TherapiesOS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies has two platform technologies targeting solid tumors: OST-HER2 PhIIb immuno-oncology to prevent metastasis, and OST-TDC pre-clinical next generation Tunable Drug Conjugate with ph-variable SiLinker linkers and multiple Conditionally Active Payloads (CAPs).
Shanghai Huaota BiopharmaceuticalHuaota has built comprehensive and integrated platforms to develop novel biologics. The R&D platform at Huaota supports identifying and developing new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc. Huaota has a diverse product pipeline covering therapeutic areas such as tumors and autoimmune diseases. At present, there are over twenty projects under development. Many of them have obtained IND approval and multiple clinical trials are undertaken in the United States, New Zealand, and China. 
HanchorBioHanchorBio Group, established in November 2020, is a biotech company developing a multifunctional FBDB®-based fusion protein platform by its founder, former CEO of Helius, Dr. Shi-Kau Liu, with teams in Taiwan, China and worldwide for preclinical R&D. HanchorBio is dedicated to helping patients with immunotherapy-resistant tumors and has also developed several immunotherapy and cytokine drugs simultaneously. 
Aston Sci. Aston Science is a clinical stage biopharmaceutical company focusing on basic research and clinical development for various therapeutic cancer vaccines, headquartered in Seoul, Korea. We are an innovative-oriented biotech have rich scientific assets among therapeutic cancer vaccine industry around the world. And we have University of Washington and Epithany Inc. as strategic R&D partners for current and upcoming cancer vaccine assets in the cancer immunotherapy field.